Ocular complications of childhood rheumatic diseases: Uveitis

Current Rheumatology Reports

Volumn 8, Issue 6, 2006, Pages 459-468

  Reiff, Andreas ^a  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEMTUZUMAB; CORTICOSTEROID; CYCLOSPORIN A; DACLIZUMAB; ETANERCEPT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERLEUKIN 2 RECEPTOR ANTIBODY; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MYDRIATIC AGENT; RAPAMYCIN; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY;

ABDOMINAL INFECTION; ALOPECIA; ANTIBODY BLOOD LEVEL; AORTA ARCH SYNDROME; BEHCET DISEASE; BLINDNESS; CATARACT; CHILDHOOD DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG DOSE INCREASE; EYE INFLAMMATION; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; MEDICAL SPECIALIST; MUCOCUTANEOUS LYMPH NODE SYNDROME; PERITONSILLAR ABSCESS; PNEUMONIA; RETINA DETACHMENT; RETINA MACULA EDEMA; REVIEW; SARCOIDOSIS; SIDE EFFECT; SINUSITIS; SPONDYLOARTHROPATHY; SYSTEMIC LUPUS ERYTHEMATOSUS; UVEITIS; VASCULITIS; WEGENER GRANULOMATOSIS;

CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; HUMANS; RHEUMATIC DISEASES; UVEITIS, ANTERIOR; UVEITIS, POSTERIOR;

EID: 33846324029     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-006-0042-2     Document Type: Review

References (110)

1. Petty RE: Ocular complications of rheumatic diseases of childhood. Clin Orthop Relat Res 1990, 259:51-59.
2. Thadani SM, Foster CS: Treatment of ocular inflammation in children. Paediatr Drugs 2004, 6:289-301.
3. •• Becker MD, Smith JR, Max R, Fiehn C: Management of sight-threatening uveitis: new therapeutic options. Drugs 2005, 65:497-519. Comprehensive review of uveitis treatment options.
4. Murray PI, Clay CD, Mappin C, Salmon M: Molecular analysis of resolving immune responses in uveitis. Clin Exp Immunol 1999, 117:455-461.
5. Muhaya M, Calder VL, Towler H, et al.: Characterization of phenotype and cytokine profiles of T cell lines derived from the vitreous humor in ocular inflammation in man. Clin Exp Immunol 1999, 116:410-414.
6. Calder VL, Shaer B, Muhaya M, et al.: Increased CD4+ expression and decreased IL-10 in the anterior chamber in idiopathic uveitis. Invest Ophthalmol Vis Sci 1999, 40:2019-2024.
7. Muhaya M, Calder V, Towler HM, et al.: Characterization of T cells and cytokines in the aqueous humour (AH) in patients with Fuchs' heterochromic cyclitis (FHC) and idiopathic anterior uveitis (IAU). Clin Exp Immunol 1998, 111:123-128.
8. Lacomba MS, Martin CM, Gallardo Galera JM, et al.: Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis. Ophthalmic Res 2001, 33:251-255.
9. •• Noma H, Funatsu H, Yamasaki M, et al.: Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular ettdothelial growth factor and interleukin-6. Am J Ophthalmol 2005, 140:256-261. Excellent review about the pathogenesis of inflammatory eye disease.
10. Lacomba MS, Martin CM, Chamond RR, et al.: Aqueous and serum interferon gamma, interleukin (IL) 2, IL-4, and IL-10 in patients with uveitis. Arch Ophthal 2000, 118:768-772.
11. El-Shabrawi Y, Livir-Rallatos C, Christen W, et al.: High levels of interleukin-12 in the aqueous humor and vitreous of patients with uveitis. Ophthalmology 1998, 105:1659-1663.
12. de Boer JH, Hack CE, Verhoeven AJ, et al.: Chemoattractant and neutrophil degranulation activities related to interleukin-8 in vitreous fluid in uveitis and vitreo-retinal disorders. Invest Ophthalmol Vis Sci 1993, 34:3376-3385.
13. Perez VL, Papaliodis GN, Chu D, et al.: Elevated levels of interleukin 6 in the vitreous fluid of patients with pars planitis and posterior uveitis: the Massachusetts eye & ear experience and review of previous studies. Ocul Immunol Inflamm 2004, 12:193-201.
14. Franks WA, Limb GA, Stanford MR, et al.: Cytokines in human intraocular inflammation. Curr Eye Res 1992, 11(Suppl):187- 191.
15. Hooks JJ, Chan CC, Detrick B: Identification of the lymphokines, interferon-gamma and interleukin-2, in inflammatory eye diseases. Invest Ophthalmol Vis Sci 1988, 29:1444-1451.
16. Norose K, Yano A, Wang XC, et al.: Dominance of activated T cells and interleukin-6 in aqueous humor in Vogt-Koyanagi-Harada disease. Invest Ophthalmol Vis Sci 1994, 35:33-39.
17. Gritz DC, Wong IG: Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study. Ophthalmology 2004, 111:491-500.
18. Darrell RW, Wagener HP, Kurland LT: Epidemiology of uveitis. Incidence and prevalence in a small urban community. Arch Ophthalmol 1962, 68:502-514.
19. Edelsten C, Reddy MA, Stanford MR, Graham EM: Visual loss associated with pediatric uveitis in english primary and referral centers. Am J Ophthalmol 2003, 135:676-680.
20. Paivonsalo-Hietanen T, Tuominen J, Saari KM: Uveitis in children: population-based study in Finland. Acta Ophthalmol Scand 2000, 78:84-88.
21. Cassidy JT, Sullivan DB, Petty RE: Clinical patterns of chronic iridocyclitis in children with juvenile rheumatoid arthritis. Arthritis Rheum 1977, 20(2 Suppl):224.
22. Chylack LT Jr: The ocular manifestations of juvenile rheumatoid arthritis. Arthritis Rheum 1977, 20:217-223.
23. Zierhut M, Michels H, Stubiger N, et al.: Uveitis in children. Int Ophthalmol Clin 2005, 45:135-156.
24. Kanski JJ, Shun-Shin GA: Systemic uveitis syndromes in childhood: an analysis of 340 cases. Ophthalmology 1984, 91:1247-1252.
25. Tugal-Tutkin I, Havrlikova K, Power WJ, et al.: Changing patterns in uveitis in childhood. Ophthalmology 1996, 103:375-383.
26. Kotaniemi K, Kautiainen H, Karma A, Aho K: Occurrence of uveitis in recently diagnosed juvenile chronic arthritis: a prospective study. Ophthalmology 2001, 108:2071-2075.
27. Cassidy JT, Sullivan DB, Petty RE: Clinical patterns of chronic iridocyclitis in children with juvenile rheumatoid arthritis. Arthritis Rheum 1977, 20:224-226.
28. Cassidy JT: Juvenile rheumatoid arthritis. In Kelley's Textbook of Rheumatology. Edited by Kelley WN, Harris ED Jr, Ruddy S, Sledge CB. Philadelphia: Saunders; 2004:1189-1208.
29. Cunningham ET Jr: Uveitis in children. Ocul Immunol Inflamm 2000, 8:251-261.
30. Stoffel PB, Sauvain MJ, von Vigier RO, et al.: Non-infectious causes of uveitis in 70 Swiss children. Acta Paediatr 2000, 89:955-958.
31. Kadayifcilar S, Eldem B, Turner B: Uveitis in childhood. J Pediatr Ophthalmol Strabismus 2003, 40:335-401.
32. Rosenberg AM: Uveitis associated with juvenile idiopathic arthritis: envisioning the future. J Rheumatol 2002, 29:2253-2255.
33. Dana MR, Merayo-Lloyes J, Schaumberg DA, Foster CS: Visual outcomes prognosticators in juvenile rheumatoid arthritis-associated uveitis. Ophthalmology 1997, 104: 236-244.
34. Cabral DA, Petty RE, Malleson PN, et al.: Visual prognosis in children with chronic anterior uveitis and arthritis. J Rheumatol 21:2370-2375.
35. Ozdal PC, Vianna RN, Deschenes J: Visual outcome of juvenile rheumatoid arthritis-associated uveitis in adults. Ocul Immunol Inflamm 2005, 13:33-38.
36. Petty RE, Smith JR, Rosenbaum JT: Arthritis and uveitis in children. A pediatric rheumatology perspective. Am J Ophthalmol 2003, 135:879-884.
37. Lyons JL, Rosenbaum JT: Uveitis associated with inflammatory bowel disease compared with uveitis associated with spondyloarthropathy. Arch Ophthal 1997, 115:61-64.
38. Linssen A, Rothova A, Valkenburg HA, et al.: The lifetime cumulative incidence of acute anterior uveitis in a normal population and its relation to ankylosing spondylitis and histocompatibility antigen HLA-B27. Invest Ophthalmol Vis Sci 1991, 32:2568-2578.
39. Menkes CJ, Job-Deslandre C, Feldmann JL: Juvenile-onset ankylosing spondylitis [in French]. Sem Hop 1984, 60:543-546.
40. Jacobs JC, Berdon WE, Johnston AD: HLA-B27-associated spondyloarthritis and enthesopathy in childhood: clinical, pathologic, and radiographic observations in 58 patients. J Pediatr 1982, 100:521-528.
41. Burgos-Vargas R, Howard A, Ansell BM: Antibodies to peptidoglycan in juvenile onset ankylosing spondylitis and pauciarticular onset juvenile arthritis associated with chronic iridocyclitis. J Rheumatol 1986, 13:760-762.
42. Burns JC, Joffe L, Sargent RA, Glode MP: Anterior uveitis associated with Kawasaki syndrome. Pediatr Infect Dis 1985, 4:258-261.
43. Jacob JL, Polomeno RC, Chad Z, Lapointe N: Ocular manifestations of Kawasaki disease (mucocutaneous lymph node syndrome). Can J Ophthalmol 1982, 17:199-202.
44. Ohno S, Miyajima T, Higuchi M, et al.: Ocular manifestations of Kawasaki's disease (mucocutaneous lymph node syndrome). Am J Ophthalmol 1982, 93:713-717.
45. Lapointe N, Chad Z, Lacroix J, et al.: Kawasaki disease: association with uveitis in seven patients. Pediatrics 1982, 69:376-378.
46. Offret H: Disciform keratitis and Kawasaki's disease [in French]. J Fr Ophtalmol 1993, 16:114-116.
47. Ocular manifestations of Kawasaki's disease (mucocutaneous lymph node syndrome). Am J Ophthalmol 1982, 93:713-717.
48. Burke MJ, Rennebohm RM: Eye involvement in Kawasaki disease. J Pediatr Ophthalmol Strabismus 1981, 18:7-11.
49. Burke MJ, Rennebohm RM, Crowe W, Levinson JE: Follow-up ophthalmologic examinations in children with Kawasaki's disease. Am J Ophthalmol 1981, 91:537-539.
50. Rennebohm RM, Burke MJ, Crowe W, Levinson JE: Anterior uveitis in Kawasaki's disease. Am J Ophthalmol 1981, 91:535-537.
51. Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, et al.: Uveitis in Behcet disease: an analysis of 880 patients. Am J Ophthalmol 2004, 138:373-380.
52. Laghmari M, Karim A, Allali F, et al.: Childhood Behcet's disease: clinical and evolutive aspects. About 13 cases [in French]. J Fr Ophtalmol 2002, 25:904-908.
53. Kim DK, Chang SN, Bang D, et al.: Clinical analysis of 40 cases of childhood-onset Behcet's disease. Pediatr Dermatol 1994, 11:95-101.
54. Pivetti-Pezzi P, Accorinti M, Abdulaziz MA, et al.: Behcets disease in children. Jpn J Ophthalmol 1995, 39:309-314.
55. Hoover DL, Khan JA, Giangiacomo J: Pediatric ocular sarcoidosis. Surv Ophthalmol 1986, 30:215-228.
56. Obenauf CD, Shaw HE, Sydnor CF, Klintworth GK: Sarcoidosis and its ophthalmic manifestations. Am J Ophthalmol 1978, 86:648-655.
57. Mar Sahn EE, Hampton MT, Garen PD, et al.: Preschool sarcoidosis masquerading as juvenile rheumatoid arthritis: two case reports and a review of the literature. Pediatr Dermatol 1990, 7:208-213.
58. Khan JA, Hoover DL, Giangiacomo J, Singsen BH: Orbital and childhood sarcoidosis. J Pediatr Ophthalmol Strabismus 1986, 23:190-194.
59. Henkind P: Sarcoidosis: an expanding ophthalmic horizon. J R Soc Med 1982, 75:153-159.
60. Karma A: Incidence of uveitis due to sarcoidosis in Northern Finland. Acta Ophthalmol 1979, 57:942-943.
61. Obenauf CD, Shaw HE, Sydnor CF, Klintworth GK: Sarcoidosis and its ophthalmic manifestations. Am J Ophthalmol 1978, 86:648-655.
62. Bullen CL, Liesegang TJ, McDonald TJ, DeRemee RA: Ocular complications of Wegener's granulomatosis. Ophthalmology 1983, 90:279-290.
63. Becker RW, Sohn RL, Poulik JM, Berguer R: Takayasu's arteritis presenting as uveitis in a 5-year-old girl. Ann Vasc Surg 2005, 19:258-262.
64. McDonald MA, Ojaimi E, Favilla I: Anterior uveitis in a child with Takayasu's arteritis. Clin Experiment Ophthalmol 2004, 32:336-339.
65. Kausman JY, Walker A, Piper S: Acute panuveitis and Takayasu's arteritis. Arch Dis Child 2003, 88:938-939.
66. Al-Mayouf SM, Al-Hemidan AI: Ocular manifestations of systemic lupus erythematosus in children. Saudi Med J 2003, 24:964-966.
67. Chylack LT Jr: The ocular manifestations of juvenile rheumatoid arthritis. Arthritis Rheum 1977, 20:217-223.
68. Nguyen QD, Foster CS: Saving the vision of children with juvenile rheumatoid arthritis-associated uveitis. JAMA 1998, 280:1133-1134.
69. Jabs DA, Rosenbaum JT, Foster CS, et al.: Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 2000, 130:492-513.
70. Samson CM, Waheed N, Baltatzis S, Foster CS: Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients. Ophthalmology 2001, 108:1134-1139.
71. Weiss AH, Wallace CA, Sherry DD: Methotrexate for resistant chronic uveitis in children with juvenile rheumatoid arthritis. J Pediatr 1998, 133:266-268.
72. Malik AR, Pavesio C: The use of low dose methotrexate in children with chronic anterior and intermediate uveitis. Br J Ophthalmol 2005, 89:806-808.
73. Foeldvari I, Wierk A: Methotrexate is an effective treatment for chronic uveitis associated with juvenile idiopathic arthritis. J Rheumatol 2005, 32:362-365.
74. Puchta J, Hattenbach LO, Baatz H: Intraocular levels of methotrexate after oral low-dose treatment in chronic uveitis. Ophthalmologica 2005, 219:54-55.
75. Kilmartin DJ, Forrester JV, Dick AD: Cyclosporin A therapy in refractory non- infectious childhood uveitis. Br J Ophthalmol 1998, 82:737-742.
76. Thorne JE, Jabs DA, Qazi FA, et al.: Rescue therapy with mycophenolate mofetil in refractory uveitis. Lancet 1998, 352:35-36.
77. Lau CH, Comer M, Lightman S: Long-term efficacy of mycophenolate mofetil in the control of severe intraocular inflammation. Clin Experiment Ophthalmol 2003, 31:487-491.
78. Kilmartin DJ, Forrester JV, Dick AD: Tacrolimus (FK506) in failed cyclosporin A therapy in endogenous posterior uveitis. Ocul Immunol Inflamm 1998, 6:101-109.
79. Mochizuki M, Masuda K, Sakane T, et al.: A clinical trial of FK506 in refractory uveitis. Am J Ophthalmol 1993, 115:763-769.
80. Gerloni V, Cimaz R, Gattinara M, et al.: Efficacy and safety profile of cyclosporin A in the treatment of juvenile chronic (idiopathic) arthritis. Results of a 10-year prospective study. Rheumatology 2001, 40:907-913.
81. Ramadan A, Nussenblatt R: Cytotoxic agents in ocular inflammation. Ophthalmol Clin North Am 1997, 10:377-387.
82. Andrasch RH, Pirofsky B, Burns RP: Immunosuppressive therapy for severe chronic uveitis. Arch Ophthalmol 1978, 96:247-251.
83. De Vos AF, Klaren VNA, Kijlstra A: Expression of multiple cytokines and IL-1RA in the uvea and retina during endotoxin-induced uveitis in the rat. Invest Ophthalmol Vis Sci 1994, 35:3873-3883.
84. Nakamura S, Yamakawa T, Sugita M, et al.: The role of tumor necrosis factor-alpha in the induction of experimental autoimmune uveoretinitis in mice. Invest Ophthalmol Vis Sci 1994, 35:3884-3889.
85. Okada AA, Sakai J, Usui M, Mizuguchi J: Intraocular cytokine quantification of experimental autoimmune uveoretinitis in rats. Ocul Immunol Inflamm 1998, 6:111-120.
86. Brito BE, O'Rourke LM, Pan Y, et al.: IL-1 and TNF receptor-deficient mice show decreased inflammation in an immune complex model of uveitis. Invest Ophthalmol Vis Sci 1999, 40:2583-2589.
87. Kasner L, Chan CC, Whitcup SM, Gery I: The paradoxical effect of tumor necrosis factor alpha (TNF-alpha) in endotoxin-induced uveitis. Invest Ophthalmol Vis Sci 1993, 34:2911-2917.
88. De Vos AF, Van Haren MA, Verhagen C, et al.: Systemic anti-tumor necrosis factor antibody treatment exacerbates endotoxin-induced uveitis in the rat. Exp Eye Res 1995, 61:667-675.
89. Dick AD, McMenamin PG, Korner H, et al.: Inhibition of tumor necrosis factor activity minimizes target organ damage in experimental autoimmune uveoretinitis despite quantitatively normal activated T cell traffic to the retina. Eur J Immunol 1996, 26:1018-1025.
90. Reiff A, Takei S, Sadeghi S, et al.: Etanercept therapy in children with treatment-resistant uveitis. Arthritis Rheum 2001, 44:1411-1415.
91. Reiff A: Long-term outcome of etanercept treatment in children with treatment refractory uveitis [letter]. Arthritis Rheum 2003, 48:2079-2080.
92. Espada G, Meiorin SM, Weissbrod P, et al.: Etanercept therapy for JIA associated refractory uveitis. Arthritis Rheum 2005, 52(Suppl): S143.
93. El-Shabrawi Y, Mangge H, Hermann J: Anti-tumour necrosis factor alpha treatment in chronic recurrent inflammation of the anterior segment of the eye in patients resistant to standard immunomodulatory treatment. Ann Rheum Dis 2003, 62:1243-1244.
94. Joseph A, Raj D, Dua HS, et al.: Infliximab in the treatment of refractory posterior uveitis. Ophthalmology 2003, 110:1449-1453.
95. Smith JR, Levinson RD, Holland GN, et al.: Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum 2001, 45:252-257.
96. Smith JA, Thompson DJ, Whitcup SM, et al.: A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum 2005, 53:18-23.
97. Reddy AR, Backhouse OC: Does etanercept induce uveitis? Br J Ophthalmol 2003, 87:925.
98. Richards JC, Tay-Kearney ML, Murray K, Manners P: Infliximab for juvenile idiopathic arthritis-associated uveitis. Clin Experiment Ophthalmol 2005, 33:461-468.
99. El-Shabrawi Y, Hermann J: Anti-tumor necrosis factor-alpha therapy with infliximab as an alternative to corticosteroids in the treatment of human leukocyte antigen B27-associated acute anterior uveitis. Ophthalmology 2002, 109:2342-2346.
100. Rajaraman RT, Kimura Y, Li S, et al.: Retrospective case review of pediatric patients with uveitis treated with infliximab. Ophthalmology 2006, 113:308-314.
101. Sfikakis PP, Theodossiadis PG, Katsiari CG, et al.: Effect of infliximab on sight threatening panuveitis in Behcet's disease. Lancet 2001, 358:295-296.
102. Saurenmann RK, Levin AV, Rose JB, et al.: Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis. Rheumatology (Oxford) 2006, 45:982-989.
103. Tynjälä P, Lindahl P, Honkanen V, et al.: Infliximab and etanercept in the treatment of refractory juvenile idiopathicarthritis associated uveitis. Arthritis Rheum 2006, in press.
104. Schmeling H, Horneff G: Etanercept and uveitis in patients with juvenile idiopathic arthritis. Rheumatology 2005, 44:1008-1011.
105. Dick AD, Meyer P, James T, et al.: Campath-1H therapy in refractory ocular inflammatory disease. Br J Ophthalmol 2000, 84:107-109.
106. Nussenblatt RB, Peterson JS, Foster CS, et al.: Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series. Ophthalmology 2005, 112:764-770.
107. Papaliodis GN, Chu D, Foster CS: Treatment of ocular inflammatory disorders with daclizumab. Ophthalmology 2003, 110:786-789.
108. Lim WK, Fujimoto C, Ursea R, et al.: Suppression of immune-mediated ocular inflammation in mice by interleukin 1 receptor antagonist administration. Arch Ophthalmol 2005, 123:957-963.
109. Vinores SA, Chan CC, Vinores MA, et al.: Increased vascular endothelial growth factor (VEGF) and transforming growth factor beta (TGF-beta) in experimental autoimmune uveoretinitis upregulation of VEGF without neovascularization. J Neuroimmunol 1998, 89:43-50.
110. Wallis RS, Ehlers S: Tumor necrosis factor and granuloma biology: explaining the differential infection risk of etanercept and infliximab. Semin Arthritis Rheum 2005, 34:34-38.